497 results
Search Results
2. Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis.
- Author
-
Schroll, Jeppe Bennekou, Penninga, Elisabeth I., and Gøtzsche, Peter C.
- Subjects
ADVERSE health care events ,RESEARCH protocols ,ORLISTAT ,FREEDOM of information ,SYSTEMATIC reviews ,BIBLIOMETRICS ,NEWSLETTERS ,OBESITY ,ORGANIC compounds ,ANTIOBESITY agents ,TREATMENT effectiveness ,STANDARDS ,THERAPEUTICS - Abstract
Background: Little is known about how adverse events are summarised and reported in trials, as detailed information is usually considered confidential. We have acquired clinical study reports (CSRs) from the European Medicines Agency through the Freedom of Information Act. The CSRs describe the results of studies conducted as part of the application for marketing authorisation for the slimming pill orlistat. The purpose of this study was to study how adverse events were summarised and reported in study protocols, CSRs, and published papers of orlistat trials.Methods and Findings: We received the CSRs from seven randomised placebo controlled orlistat trials (4,225 participants) submitted by Roche. The CSRs consisted of 8,716 pages and included protocols. Two researchers independently extracted data on adverse events from protocols and CSRs. Corresponding published papers were identified on PubMed and adverse event data were extracted from this source as well. All three sources were compared. Individual adverse events from one trial were summed and compared to the totals in the summary report. None of the protocols or CSRs contained instructions for investigators on how to question participants about adverse events. In CSRs, gastrointestinal adverse events were only coded if the participant reported that they were "bothersome," a condition that was not specified in the protocol for two of the trials. Serious adverse events were assessed for relationship to the drug by the sponsor, and all adverse events were coded by the sponsor using a glossary that could be updated by the sponsor. The criteria for withdrawal due to adverse events were in one case related to efficacy (high fasting glucose led to withdrawal), which meant that one trial had more withdrawals due to adverse events in the placebo group. Finally, only between 3% and 33% of the total number of investigator-reported adverse events from the trials were reported in the publications because of post hoc filters, though six of seven papers stated that "all adverse events were recorded." For one trial, we identified an additional 1,318 adverse events that were not listed or mentioned in the CSR itself but could be identified through manually counting individual adverse events reported in an appendix. We discovered that the majority of patients had multiple episodes of the same adverse event that were only counted once, though this was not described in the CSRs. We also discovered that participants treated with orlistat experienced twice as many days with adverse events as participants treated with placebo (22.7 d versus 14.9 d, p-value < 0.0001, Student's t test). Furthermore, compared with the placebo group, adverse events in the orlistat group were more severe. None of this was stated in the CSR or in the published paper. Our analysis was restricted to one drug tested in the mid-1990s; our results might therefore not be applicable for newer drugs.Conclusions: In the orlistat trials, we identified important disparities in the reporting of adverse events between protocols, clinical study reports, and published papers. Reports of these trials seemed to have systematically understated adverse events. Based on these findings, systematic reviews of drugs might be improved by including protocols and CSRs in addition to published articles. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Blue Marble Health: A Call for Papers.
- Author
-
Hotez, Peter J. and Peiperl, Larry
- Subjects
- *
ECONOMIC development , *TROPICAL medicine , *MEDICAL care , *EDITORS , *MARBLE - Abstract
In this month's editorial, Peter J. Hotez, Co-Editor-in-Chief of PLOS Neglected Tropical Diseases and Larry Peiperl, Chief Editor of PLOS Medicine, call for papers on “Blue Marble Health”: research on health problems that affect poorer people irrespective of the overall economic strength of the countries in which they live. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Dementia across the Lifespan and around the Globe-Pathophysiology, Prevention, Treatment, and Societal Impact: A Call for Papers.
- Author
-
null, null and PLOS Medicine Editors
- Subjects
DEMENTIA patients ,DEMENTIA prevention ,TREATMENT of dementia ,DEMENTIA ,ECONOMIC aspects of diseases ,WORLD health ,EARLY diagnosis - Abstract
In this months editorial, the PLOS Medicine Editors announce an upcoming Special Issue and call for papers, with Guest Editors Carol Brayne and Bruce Miller, on dementia across the lifespan and around the globe. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. A Collection on the prevention, diagnosis, and treatment of sexually transmitted infections: Call for research papers.
- Author
-
Low, Nicola, Broutet, Nathalie, and Turner, Richard
- Subjects
- *
SEXUALLY transmitted diseases , *MEDICAL sciences , *COMMUNICABLE diseases , *INDUSTRIAL hygiene , *UROLOGY - Abstract
Nicola Low and colleagues announce a call for research papers on sexually transmitted infections, to accompany a Collection on the topic. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. The Future of Diabetes Prevention: A Call for Papers.
- Author
-
null, null and PLOS Medicine Editors
- Subjects
DIABETES prevention ,EDITORS ,MEDICAL journalism ,PEOPLE with diabetes ,DIABETES complications ,DIABETES ,DISEASES ,NEWSLETTERS ,PREVENTIVE health services ,WORLD health - Abstract
PLOS Medicine editors and guest editors announce a call for papers for submissions for a special issue on diabetes prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Clinical Implications of Cancer Genomics: A Call for Papers.
- Author
-
null, null and PLOS Medicine Editors
- Subjects
CANCER genetics ,IMMUNOTHERAPY ,CANCER treatment ,CANCER vaccines ,BIOPSY ,CANCER diagnosis ,GENETICS ,HUMAN genome ,MEDICAL research ,NEWSLETTERS ,PUBLISHING ,TUMORS ,GENOMICS - Abstract
In this month's editorial, the PLOS Medicine Editors announce an upcoming Special Issue, with Guest Editors Elaine Mardis and Marc Ladanyi, on actionable advances in research on the cancer genome. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. The Policy Dystopia Model: An Interpretive Analysis of Tobacco Industry Political Activity.
- Author
-
Ulucanlar, Selda, Fooks, Gary J., and Gilmore, Anna B.
- Subjects
DYSTOPIAS ,POLITICAL participation ,TOBACCO industry ,GROUNDED theory ,TAXONOMY - Abstract
Background: Tobacco industry interference has been identified as the greatest obstacle to the implementation of evidence-based measures to reduce tobacco use. Understanding and addressing industry interference in public health policy-making is therefore crucial. Existing conceptualisations of corporate political activity (CPA) are embedded in a business perspective and do not attend to CPA's social and public health costs; most have not drawn on the unique resource represented by internal tobacco industry documents. Building on this literature, including systematic reviews, we develop a critically informed conceptual model of tobacco industry political activity.Methods and Findings: We thematically analysed published papers included in two systematic reviews examining tobacco industry influence on taxation and marketing of tobacco; we included 45 of 46 papers in the former category and 20 of 48 papers in the latter (n = 65). We used a grounded theory approach to build taxonomies of "discursive" (argument-based) and "instrumental" (action-based) industry strategies and from these devised the Policy Dystopia Model, which shows that the industry, working through different constituencies, constructs a metanarrative to argue that proposed policies will lead to a dysfunctional future of policy failure and widely dispersed adverse social and economic consequences. Simultaneously, it uses diverse, interlocking insider and outsider instrumental strategies to disseminate this narrative and enhance its persuasiveness in order to secure its preferred policy outcomes. Limitations are that many papers were historical (some dating back to the 1970s) and focused on high-income regions.Conclusions: The model provides an evidence-based, accessible way of understanding diverse corporate political strategies. It should enable public health actors and officials to preempt these strategies and develop realistic assessments of the industry's claims. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Causes of death and infant mortality rates among full-term births in the United States between 2010 and 2012: An observational study.
- Author
-
Bairoliya, Neha and Fink, Günther
- Subjects
PREMATURE labor ,INFANT mortality ,CAUSES of death ,SCIENTIFIC observation ,LOGISTIC model (Demography) ,PRENATAL care ,SUDDEN infant death syndrome prevention ,HUMAN abnormalities ,ASPHYXIA ,BIRTH certificates ,MATERNAL health services ,MORTALITY ,NEEDS assessment ,DURATION of pregnancy ,QUESTIONNAIRES ,SUDDEN infant death syndrome ,DEATH certificates ,EDUCATIONAL attainment ,IMPACT of Event Scale - Abstract
Background: While the high prevalence of preterm births and its impact on infant mortality in the US have been widely acknowledged, recent data suggest that even full-term births in the US face substantially higher mortality risks compared to European countries with low infant mortality rates. In this paper, we use the most recent birth records in the US to more closely analyze the primary causes underlying mortality rates among full-term births.Methods and Findings: Linked birth and death records for the period 2010-2012 were used to identify the state- and cause-specific burden of infant mortality among full-term infants (born at 37-42 weeks of gestation). Multivariable logistic models were used to assess the extent to which state-level differences in full-term infant mortality (FTIM) were attributable to observed differences in maternal and birth characteristics. Random effects models were used to assess the relative contribution of state-level variation to FTIM. Hypothetical mortality outcomes were computed under the assumption that all states could achieve the survival rates of the best-performing states. A total of 10,175,481 infants born full-term in the US between January 1, 2010, and December 31, 2012, were analyzed. FTIM rate (FTIMR) was 2.2 per 1,000 live births overall, and ranged between 1.29 (Connecticut, 95% CI 1.08, 1.53) and 3.77 (Mississippi, 95% CI 3.39, 4.19) at the state level. Zero states reached the rates reported in the 6 low-mortality European countries analyzed (FTIMR < 1.25), and 13 states had FTIMR > 2.75. Sudden unexpected death in infancy (SUDI) accounted for 43% of FTIM; congenital malformations and perinatal conditions accounted for 31% and 11.3% of FTIM, respectively. The largest mortality differentials between states with good and states with poor FTIMR were found for SUDI, with particularly large risk differentials for deaths due to sudden infant death syndrome (SIDS) (odds ratio [OR] 2.52, 95% CI 1.86, 3.42) and suffocation (OR 4.40, 95% CI 3.71, 5.21). Even though these mortality differences were partially explained by state-level differences in maternal education, race, and maternal health, substantial state-level variation in infant mortality remained in fully adjusted models (SIDS OR 1.45, suffocation OR 2.92). The extent to which these state differentials are due to differential antenatal care standards as well as differential access to health services could not be determined due to data limitations. Overall, our estimates suggest that infant mortality could be reduced by 4,003 deaths (95% CI 2,284, 5,587) annually if all states were to achieve the mortality levels of the best-performing state in each cause-of-death category. Key limitations of the analysis are that information on termination rates at the state level was not available, and that causes of deaths may have been coded differentially across states.Conclusions: More than 7,000 full-term infants die in the US each year. The results presented in this paper suggest that a substantial share of these deaths may be preventable. Potential improvements seem particularly large for SUDI, where very low rates have been achieved in a few states while average mortality rates remain high in most other areas. Given the high mortality burden due to SIDS and suffocation, policy efforts to promote compliance with recommended sleeping arrangements could be an effective first step in this direction. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
10. Monitoring and Evaluating Progress towards Universal Health Coverage in Ethiopia.
- Author
-
Alebachew, Abebe, Hatt, Laurel, and Kukla, Matthew
- Subjects
HEALTH insurance ,HEALTH promotion ,HEALTH services accessibility ,HEALTH services administration ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Abebe Alebachew and colleagues illustrate progress towards UHC and its monitoring and evaluation in Ethiopia. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Incidence of eclampsia and related complications across 10 low- and middle-resource geographical regions: Secondary analysis of a cluster randomised controlled trial.
- Author
-
Vousden, Nicola, Lawley, Elodie, Seed, Paul T., Gidiri, Muchabayiwa Francis, Goudar, Shivaprasad, Sandall, Jane, Chappell, Lucy C., Shennan, Andrew H., null, null, and CRADLE Trial Collaborative Group
- Subjects
ECLAMPSIA ,SECONDARY analysis ,HEALTH facilities ,BIRTHING centers ,MAGNESIUM sulfate ,STILLBIRTH ,MATERNAL mortality - Abstract
Background: In 2015, approximately 42,000 women died as a result of hypertensive disorders of pregnancy worldwide; over 99% of these deaths occurred in low- and middle-income countries. The aim of this paper is to describe the incidence and characteristics of eclampsia and related complications from hypertensive disorders of pregnancy across 10 low- and middle-income geographical regions in 8 countries, in relation to magnesium sulfate availability.Methods and Findings: This is a secondary analysis of a stepped-wedge cluster randomised controlled trial undertaken in sub-Saharan Africa, India, and Haiti. This trial implemented a novel vital sign device and training package in routine maternity care with the aim of reducing a composite outcome of maternal mortality and morbidity. Institutional-level consent was obtained, and all women presenting for maternity care were eligible for inclusion. Data on eclampsia, stroke, admission to intensive care with a hypertensive disorder of pregnancy, and maternal death from a hypertensive disorder of pregnancy were prospectively collected from routine data sources and active case finding, together with data on perinatal outcomes in women with these outcomes. In 536,233 deliveries between 1 April 2016 and 30 November 2017, there were 2,692 women with eclampsia (0.5%). In total 6.9% (n = 186; 3.47/10,000 deliveries) of women with eclampsia died, and a further 51 died from other complications of hypertensive disorders of pregnancy (0.95/10,000). After planned adjustments, the implementation of the CRADLE intervention was not associated with any significant change in the rates of eclampsia, stroke, or maternal death or intensive care admission with a hypertensive disorder of pregnancy. Nearly 1 in 5 (17.9%) women with eclampsia, stroke, or a hypertensive disorder of pregnancy causing intensive care admission or maternal death experienced a stillbirth or neonatal death. A third of eclampsia cases (33.2%; n = 894) occurred in women under 20 years of age, 60.0% in women aged 20-34 years (n = 1,616), and 6.8% (n = 182) in women aged 35 years or over. Rates of eclampsia varied approximately 7-fold between sites (range 19.6/10,000 in Zambia Centre 1 to 142.0/10,000 in Sierra Leone). Over half (55.1%) of first eclamptic fits occurred in a health-care facility, with the remainder in the community. Place of first fit varied substantially between sites (from 5.9% in the central referral facility in Sierra Leone to 85% in Uganda Centre 2). On average, magnesium sulfate was available in 74.7% of facilities (range 25% in Haiti to 100% in Sierra Leone and Zimbabwe). There was no detectable association between magnesium sulfate availability and the rate of eclampsia across sites (p = 0.12). This analysis may have been influenced by the selection of predominantly urban and peri-urban settings, and by collection of only monthly data on availability of magnesium sulfate, and is limited by the lack of demographic data in the population of women delivering in the trial areas.Conclusions: The large variation in eclampsia and maternal and neonatal fatality from hypertensive disorders of pregnancy between countries emphasises that inequality and inequity persist in healthcare for women with hypertensive disorders of pregnancy. Alongside the growing interest in improving community detection and health education for these disorders, efforts to improve quality of care within healthcare facilities are key. Strategies to prevent eclampsia should be informed by local data.Trial Registration: ISRCTN: 41244132. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. Independent and combined effects of improved water, sanitation, and hygiene (WASH) and improved complementary feeding on early neurodevelopment among children born to HIV-negative mothers in rural Zimbabwe: Substudy of a cluster-randomized trial.
- Author
-
Gladstone, Melissa J., Chandna, Jaya, Kandawasvika, Gwendoline, Ntozini, Robert, Majo, Florence D., Tavengwa, Naume V., Mbuya, Mduduzi N. N., Mangwadu, Goldberg T., Chigumira, Ancikaria, Chasokela, Cynthia M., Moulton, Lawrence H., Stoltzfus, Rebecca J., Humphrey, Jean H., Prendergast, Andrew J., null, null, and SHINE Trial Team
- Subjects
COMMUNITY health workers ,SANITATION ,HYGIENE ,CHILD care ,INFANT nutrition - Abstract
Background: Globally, nearly 250 million children (43% of all children under 5 years of age) are at risk of compromised neurodevelopment due to poverty, stunting, and lack of stimulation. We tested the independent and combined effects of improved water, sanitation, and hygiene (WASH) and improved infant and young child feeding (IYCF) on early child development (ECD) among children enrolled in the Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial in rural Zimbabwe.Methods and Findings: SHINE was a cluster-randomized community-based 2×2 factorial trial. A total of 5,280 pregnant women were enrolled from 211 clusters (defined as the catchment area of 1-4 village health workers [VHWs] employed by the Zimbabwean Ministry of Health and Child Care). Clusters were randomly allocated to standard of care, IYCF (20 g of small-quantity lipid-based nutrient supplement per day from age 6 to 18 months plus complementary feeding counseling), WASH (ventilated improved pit latrine, handwashing stations, chlorine, liquid soap, and play yard), and WASH + IYCF. Primary outcomes were child length-for-age Z-score and hemoglobin concentration at 18 months of age. Children who completed the 18-month visit and turned 2 years (102-112 weeks) between March 1, 2016, and April 30, 2017, were eligible for the ECD substudy. We prespecified that primary inferences would be drawn from findings of children born to HIV-negative mothers; these results are presented in this paper. A total of 1,655 HIV-unexposed children (64% of those eligible) were recruited into the ECD substudy from 206 clusters and evaluated for ECD at 2 years of age using the Malawi Developmental Assessment Tool (MDAT) to assess gross motor, fine motor, language, and social skills; the MacArthur-Bates Communicative Development Inventories (CDI) to assess vocabulary and grammar; the A-not-B test to assess object permanence; and a self-control task. Outcomes were analyzed in the intention-to-treat population. For all ECD outcomes, there was not a statistical interaction between the IYCF and WASH interventions, so we estimated the effects of the interventions by comparing the 2 IYCF groups with the 2 non-IYCF groups and the 2 WASH groups with the 2 non-WASH groups. The mean (95% CI) total MDAT score was modestly higher in the IYCF groups compared to the non-IYCF groups in unadjusted analysis: 1.35 (0.24, 2.46; p = 0.017); this difference did not persist in adjusted analysis: 0.79 (-0.22, 1.68; p = 0.057). There was no evidence of impact of the IYCF intervention on the CDI, A-not-B, or self-control tests. Among children in the WASH groups compared to those in the non-WASH groups, mean scores were not different for the MDAT, A-not-B, or self-control tests; mean CDI score was not different in unadjusted analysis (0.99 [95% CI -1.18, 3.17]) but was higher in children in the WASH groups in adjusted analysis (1.81 [0.01, 3.61]). The main limitation of the study was the specific time window for substudy recruitment, meaning not all children from the main trial were enrolled.Conclusions: We found little evidence that the IYCF and WASH interventions implemented in SHINE caused clinically important improvements in child development at 2 years of age. Interventions that directly target neurodevelopment (e.g., early stimulation) or that more comprehensively address the multifactorial nature of neurodevelopment may be required to support healthy development of vulnerable children.Trial Registration: ClinicalTrials.gov NCT01824940. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
13. The effect of a programme to improve men's sedentary time and physical activity: The European Fans in Training (EuroFIT) randomised controlled trial.
- Author
-
Wyke, Sally, Bunn, Christopher, Gray, Cindy M., Macaulay, Lisa, Loudon, David W., Maxwell, Douglas J., Mutrie, Nanette, Nijhuis-van der Sanden, Maria, van de Glind, Irene, Philpott, Matthew, Rooksby, John, Treweek, Shaun, van Achterberg, Theo, Andersen, Eivind, Lemyre, Nicolas, Roberts, Glyn C., Røynesdal, Øystein B., Sørensen, Marit, Silva, Marlene N., and Pereira, Hugo V.
- Abstract
Background: Reducing sitting time as well as increasing physical activity in inactive people is beneficial for their health. This paper investigates the effectiveness of the European Fans in Training (EuroFIT) programme to improve physical activity and sedentary time in male football fans, delivered through the professional football setting.Methods and Findings: A total of 1,113 men aged 30-65 with self-reported body mass index (BMI) ≥27 kg/m2 took part in a randomised controlled trial in 15 professional football clubs in England, the Netherlands, Norway, and Portugal. Recruitment was between September 19, 2015, and February 2, 2016. Participants consented to study procedures and provided usable activity monitor baseline data. They were randomised, stratified by club, to either the EuroFIT intervention or a 12-month waiting list comparison group. Follow-up measurement was post-programme and 12 months after baseline. EuroFIT is a 12-week, group-based programme delivered by coaches in football club stadia in 12 weekly 90-minute sessions. Weekly sessions aimed to improve physical activity, sedentary time, and diet and maintain changes long term. A pocket-worn device (SitFIT) allowed self-monitoring of sedentary time and daily steps, and a game-based app (MatchFIT) encouraged between-session social support. Primary outcome (objectively measured sedentary time and physical activity) measurements were obtained for 83% and 85% of intervention and comparison participants. Intention-to-treat analyses showed a baseline-adjusted mean difference in sedentary time at 12 months of -1.6 minutes/day (97.5% confidence interval [CI], -14.3-11.0; p = 0.77) and in step counts of 678 steps/day (97.5% CI, 309-1.048; p < 0.001) in favor of the intervention. There were significant improvements in diet, weight, well-being, self-esteem, vitality, and biomarkers of cardiometabolic health in favor of the intervention group, but not in quality of life. There was a 0.95 probability of EuroFIT being cost-effective compared with the comparison group if society is willing to pay £1.50 per extra step/day, a maximum probability of 0.61 if society is willing to pay £1,800 per minute less sedentary time/day, and 0.13 probability if society is willing to pay £30,000 per quality-adjusted life-year (QALY). It was not possible to blind participants to group allocation. Men attracted to the programme already had quite high levels of physical activity at baseline (8,372 steps/day), which may have limited room for improvement. Although participants came from across the socioeconomic spectrum, a majority were well educated and in paid work. There was an increase in recent injuries and in upper and lower joint pain scores post-programme. In addition, although the five-level EuroQoL questionnaire (EQ-5D-5L) is now the preferred measure for cost-effectiveness analyses across Europe, baseline scores were high (0.93), suggesting a ceiling effect for QALYs.Conclusion: Participation in EuroFIT led to improvements in physical activity, diet, body weight, and biomarkers of cardiometabolic health, but not in sedentary time at 12 months. Within-trial analysis suggests it is not cost-effective in the short term for QALYs due to a ceiling effect in quality of life. Nevertheless, decision-makers may consider the incremental cost for increase in steps worth the investment.Trial Registration: International Standard Randomised Controlled Trials, ISRCTN-81935608. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
14. How to Make More Published Research True.
- Author
-
Ioannidis, John P. A.
- Subjects
REPRODUCIBLE research ,RESEARCH ,TRUTHFULNESS & falsehood ,PROFESSIONAL peer review ,INFORMATION dissemination ,LABOR supply ,STANDARDS - Abstract
: In a 2005 paper that has been accessed more than a million times, John Ioannidis explained why most published research findings were false. Here he revisits the topic, this time to address how to improve matters. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Monitoring Progress towards Universal Health Coverage at Country and Global Levels.
- Author
-
Boerma, Ties, Eozenou, Patrick, Evans, David, Evans, Tim, Kieny, Marie-Paule, and Wagstaff, Adam
- Subjects
HEALTH insurance ,HEALTH promotion ,MEDICAL rehabilitation ,PALLIATIVE treatment ,MEDICAL care - Abstract
: As part of the Collection on Monitoring Universal Health Coverage, Ties Boerma and colleagues discuss the key findings from the country case studies and technical reviews included in the Collection and, also, how these papers will help with the development of a global framework for monitoring progress towards Universal Health Coverage. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
16. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis.
- Author
-
Udler, Miriam S., Kim, Jaegil, von Grotthuss, Marcin, Bonàs-Guarch, Sílvia, Cole, Joanne B., Chiou, Joshua, null, null, Boehnke, Michael, Laakso, Markku, Atzmon, Gil, Glaser, Benjamin, Mercader, Josep M., Gaulton, Kyle, Flannick, Jason, Getz, Gad, Florez, Jose C., and Christopher D. Anderson on behalf of METASTROKE and the ISGC
- Subjects
TYPE 2 diabetes ,LOCUS (Genetics) ,MEDICAL care ,BIOLOGICAL tags ,INSULIN resistance ,BODY mass index - Abstract
Background: Type 2 diabetes (T2D) is a heterogeneous disease for which (1) disease-causing pathways are incompletely understood and (2) subclassification may improve patient management. Unlike other biomarkers, germline genetic markers do not change with disease progression or treatment. In this paper, we test whether a germline genetic approach informed by physiology can be used to deconstruct T2D heterogeneity. First, we aimed to categorize genetic loci into groups representing likely disease mechanistic pathways. Second, we asked whether the novel clusters of genetic loci we identified have any broad clinical consequence, as assessed in four separate subsets of individuals with T2D.Methods and Findings: In an effort to identify mechanistic pathways driven by established T2D genetic loci, we applied Bayesian nonnegative matrix factorization (bNMF) clustering to genome-wide association study (GWAS) results for 94 independent T2D genetic variants and 47 diabetes-related traits. We identified five robust clusters of T2D loci and traits, each with distinct tissue-specific enhancer enrichment based on analysis of epigenomic data from 28 cell types. Two clusters contained variant-trait associations indicative of reduced beta cell function, differing from each other by high versus low proinsulin levels. The three other clusters displayed features of insulin resistance: obesity mediated (high body mass index [BMI] and waist circumference [WC]), "lipodystrophy-like" fat distribution (low BMI, adiponectin, and high-density lipoprotein [HDL] cholesterol, and high triglycerides), and disrupted liver lipid metabolism (low triglycerides). Increased cluster genetic risk scores were associated with distinct clinical outcomes, including increased blood pressure, coronary artery disease (CAD), and stroke. We evaluated the potential for clinical impact of these clusters in four studies containing individuals with T2D (Metabolic Syndrome in Men Study [METSIM], N = 487; Ashkenazi, N = 509; Partners Biobank, N = 2,065; UK Biobank [UKBB], N = 14,813). Individuals with T2D in the top genetic risk score decile for each cluster reproducibly exhibited the predicted cluster-associated phenotypes, with approximately 30% of all individuals assigned to just one cluster top decile. Limitations of this study include that the genetic variants used in the cluster analysis were restricted to those associated with T2D in populations of European ancestry.Conclusion: Our approach identifies salient T2D genetically anchored and physiologically informed pathways, and supports the use of genetics to deconstruct T2D heterogeneity. Classification of patients by these genetic pathways may offer a step toward genetically informed T2D patient management. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. malERA: An updated research agenda for characterising the reservoir and measuring transmission in malaria elimination and eradication.
- Author
-
null, null and malERA Refresh Consultative Panel on Characterising the Reservoir and Measuring Transmission
- Subjects
MALARIA prevention ,DISEASE eradication ,RESERVOIRS ,INFECTION ,VECTOR control ,MALARIA transmission ,PROTOZOA physiology ,PREVENTION of infectious disease transmission ,MALARIA ,MEDICAL research ,MOSQUITOES ,PUBLIC health - Abstract
This paper summarises key advances in defining the infectious reservoir for malaria and the measurement of transmission for research and programmatic use since the Malaria Eradication Research Agenda (malERA) publication in 2011. Rapid and effective progress towards elimination requires an improved understanding of the sources of transmission as well as those at risk of infection. Characterising the transmission reservoir in different settings will enable the most appropriate choice, delivery, and evaluation of interventions. Since 2011, progress has been made in a number of areas. The extent of submicroscopic and asymptomatic infections is better understood, as are the biological parameters governing transmission of sexual stage parasites. Limitations of existing transmission measures have been documented, and proof-of-concept has been established for new innovative serological and molecular methods to better characterise transmission. Finally, there now exists a concerted effort towards the use of ensemble datasets across the spectrum of metrics, from passive and active sources, to develop more accurate risk maps of transmission. These can be used to better target interventions and effectively monitor progress toward elimination. The success of interventions depends not only on the level of endemicity but also on how rapidly or recently an area has undergone changes in transmission. Improved understanding of the biology of mosquito-human and human-mosquito transmission is needed particularly in low-endemic settings, where heterogeneity of infection is pronounced and local vector ecology is variable. New and improved measures of transmission need to be operationally feasible for the malaria programmes. Outputs from these research priorities should allow the development of a set of approaches (applicable to both research and control programmes) that address the unique challenges of measuring and monitoring transmission in near-elimination settings and defining the absence of transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication.
- Author
-
null, null and malERA Refresh Consultative Panel on Insecticide and Drug Resistance
- Subjects
INSECTICIDE resistance ,DRUG resistance ,MALARIA prevention ,DISEASE eradication ,VECTOR control ,DRUG therapy for malaria ,ANIMALS ,ANTIMALARIALS ,INSECTICIDES ,MALARIA ,PEST control ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
Resistance to first-line treatments for Plasmodium falciparum malaria and the insecticides used for Anopheles vector control are threatening malaria elimination efforts. Suboptimal responses to drugs and insecticides are both spreading geographically and emerging independently and are being seen at increasing intensities. Whilst resistance is unavoidable, its effects can be mitigated through resistance management practices, such as exposing the parasite or vector to more than one selective agent. Resistance contributed to the failure of the 20th century Global Malaria Eradication Programme, and yet the global response to this issue continues to be slow and poorly coordinated-too often, too little, too late. The Malaria Eradication Research Agenda (malERA) Refresh process convened a panel on resistance of both insecticides and antimalarial drugs. This paper outlines developments in the field over the past 5 years, highlights gaps in knowledge, and proposes a research agenda focused on managing resistance. A deeper understanding of the complex biological processes involved and how resistance is selected is needed, together with evidence of its public health impact. Resistance management will require improved use of entomological and parasitological data in decision making, and optimisation of the useful life of new and existing products through careful implementation, combination, and evaluation. A proactive, collaborative approach is needed from basic science and the development of new tools to programme and policy interventions that will ensure that the armamentarium of drugs and insecticides is sufficient to deal with the challenges of malaria control and its elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. malERA: An updated research agenda for health systems and policy research in malaria elimination and eradication.
- Author
-
null, null and malERA Refresh Consultative Panel on Health Systems and Policy Research
- Subjects
MALARIA prevention ,CRISIS management ,DISEASE eradication ,HEALTH policy ,PUBLIC health ,ANIMALS ,MALARIA ,MEDICAL care ,MEDICAL research - Abstract
Health systems underpin disease elimination and eradication programmes. In an elimination and eradication context, innovative research approaches are needed across health systems to assess readiness for programme reorientation, mitigate any decreases in effectiveness of interventions ('effectiveness decay'), and respond to dynamic and changing needs. The malaria eradication research agenda (malERA) Refresh consultative process for the Panel on Health Systems and Policy Research identifies opportunities to build health systems evidence and the tools needed to eliminate malaria from different zones, countries, and regions and to eradicate it globally. The research questions are organised as a portfolio that global health practitioners, researchers, and funders can identify with and support. This supports the promotion of an actionable and more cohesive approach to building the evidence base for scaled-up implementation of findings. Gaps and opportunities discussed in the paper include delivery strategies to meet the changing dynamics of needs of individuals, environments, and malaria programme successes; mechanisms and approaches to best support accelerated policy and financial responsiveness at national and global level to ensure timely response to evidence and needs, including in crisis situations; and systems' readiness tools and decision-support systems. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. malERA: An updated research agenda for combination interventions and modelling in malaria elimination and eradication.
- Author
-
null, null and malERA Refresh Consultative Panel on Combination Interventions and Modelling
- Subjects
MALARIA prevention ,DISEASE eradication ,INFECTIOUS disease transmission ,DRUG resistance ,INSECTICIDE resistance ,CRISIS management ,VECTOR control ,DISEASE vectors ,ANTIMALARIALS ,MALARIA ,MATHEMATICAL models ,MEDICAL research ,THEORY ,PHARMACODYNAMICS ,THERAPEUTICS - Abstract
This paper summarises key advances and priorities since the 2011 presentation of the Malaria Eradication Research Agenda (malERA), with a focus on the combinations of intervention tools and strategies for elimination and their evaluation using modelling approaches. With an increasing number of countries embarking on malaria elimination programmes, national and local decisions to select combinations of tools and deployment strategies directed at malaria elimination must address rapidly changing transmission patterns across diverse geographic areas. However, not all of these approaches can be systematically evaluated in the field. Thus, there is potential for modelling to investigate appropriate 'packages' of combined interventions that include various forms of vector control, case management, surveillance, and population-based approaches for different settings, particularly at lower transmission levels. Modelling can help prioritise which intervention packages should be tested in field studies, suggest which intervention package should be used at a particular level or stratum of transmission intensity, estimate the risk of resurgence when scaling down specific interventions after local transmission is interrupted, and evaluate the risk and impact of parasite drug resistance and vector insecticide resistance. However, modelling intervention package deployment against a heterogeneous transmission background is a challenge. Further validation of malaria models should be pursued through an iterative process, whereby field data collected with the deployment of intervention packages is used to refine models and make them progressively more relevant for assessing and predicting elimination outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.
- Author
-
null, null and malERA Refresh Consultative Panel on Tools for Malaria Elimination
- Subjects
DISEASE eradication ,MALARIA prevention ,CRISIS management ,MALARIA vaccines ,MALARIA treatment ,VECTOR control ,ANIMALS ,DISEASE vectors ,ANTIMALARIALS ,MALARIA ,MEDICAL research ,PEST control ,PHARMACODYNAMICS ,VACCINES ,THERAPEUTICS - Abstract
Since the turn of the century, a remarkable expansion has been achieved in the range and effectiveness of products and strategies available to prevent, treat, and control malaria, including advances in diagnostics, drugs, vaccines, and vector control. These advances have once again put malaria elimination on the agenda. However, it is clear that even with the means available today, malaria control and elimination pose a formidable challenge in many settings. Thus, currently available resources must be used more effectively, and new products and approaches likely to achieve these goals must be developed. This paper considers tools (both those available and others that may be required) to achieve and maintain malaria elimination. New diagnostics are needed to direct treatment and detect transmission potential; new drugs and vaccines to overcome existing resistance and protect against clinical and severe disease, as well as block transmission and prevent relapses; and new vector control measures to overcome insecticide resistance and more powerfully interrupt transmission. It is also essential that strategies for combining new and existing approaches are developed for different settings to maximise their longevity and effectiveness in areas with continuing transmission and receptivity. For areas where local elimination has been recently achieved, understanding which measures are needed to maintain elimination is necessary to prevent rebound and the reestablishment of transmission. This becomes increasingly important as more countries move towards elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
- Author
-
Eakle, Robyn, Gomez, Gabriela B., Naicker, Niven, Bothma, Rutendo, Mbogua, Judie, Cabrera Escobar, Maria A., Saayman, Elaine, Moorhouse, Michelle, Venter, W. D. Francois, Rees, Helen, null, null, and TAPS Demonstration Project Team
- Subjects
HIV ,PREVENTIVE medicine ,ANTIRETROVIRAL agents ,SEX workers ,HIV-positive persons ,ANTI-HIV agents ,COST effectiveness ,HIV infections ,LONGITUDINAL method ,PREVENTIVE health services ,SAFE sex ,SEXUAL partners ,ECONOMICS ,PSYCHOLOGY - Abstract
Background: Operational research is required to design delivery of pre-exposure prophylaxis (PrEP) and early antiretroviral treatment (ART). This paper presents the primary analysis of programmatic data, as well as demographic, behavioural, and clinical data, from the TAPS Demonstration Project, which offered both interventions to female sex workers (FSWs) at 2 urban clinic sites in South Africa.Methods and Findings: The TAPS study was conducted between 30 March 2015 and 30 June 2017, with the enrolment period ending on 31 July 2016. TAPS was a prospective observational cohort study with 2 groups receiving interventions delivered in existing service settings: (1) PrEP as part of combination prevention for HIV-negative FSWs and (2) early ART for HIV-positive FSWs. The main outcome was programme retention at 12 months of follow-up. Of the 947 FSWs initially seen in clinic, 692 were HIV tested. HIV prevalence was 49%. Among those returning to clinic after HIV testing and clinical screening, 93% of the women who were HIV-negative were confirmed as clinically eligible for PrEP (n = 224/241), and 41% (n = 110/270) of the women who were HIV-positive had CD4 counts within National Department of Health ART initiation guidelines at assessment. Of the remaining women who were HIV-positive, 93% were eligible for early ART (n = 148/160). From those eligible, 98% (n = 219/224) and 94% (n = 139/148) took up PrEP and early ART, respectively. At baseline, a substantial fraction of women had a steady partner, worked in brothels, and were born in Zimbabwe. Of those enrolled, 22% on PrEP (n = 49/219) and 60% on early ART (n = 83/139) were seen at 12 months; we observed high rates of loss to follow-up: 71% (n = 156/219) and 30% (n = 42/139) in the PrEP and early ART groups, respectively. Little change over time was reported in consistent condom use or the number of sexual partners in the last 7 days, with high levels of consistent condom use with clients and low use with steady partners in both study groups. There were no seroconversions on PrEP and 7 virological failures on early ART among women remaining in the study. Reported adherence to PrEP varied over time between 70% and 85%, whereas over 90% of participants reported taking pills daily while on early ART. Data on provider-side costs were also collected and analysed. The total cost of service delivery was approximately US$126 for PrEP and US$406 for early ART per person-year. The main limitations of this study include the lack of a control group, which was not included due to ethical considerations; clinical study requirements imposed when PrEP was not approved through the regulatory system, which could have affected uptake; and the timing of the implementation of a national sex worker HIV programme, which could have also affected uptake and retention.Conclusions: PrEP and early ART services can be implemented within FSW routine services in high prevalence, urban settings. We observed good uptake for both PrEP and early ART; however, retention rates for PrEP were low. Retention rates for early ART were similar to retention rates for the current standard of care. While the cost of the interventions was higher than previously published, there is potential for cost reduction at scale. The TAPS Demonstration Project results provided the basis for the first government PrEP and early ART guidelines and the rollout of the national sex worker HIV programme in South Africa. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. Women's and men's reports of past-year prevalence of intimate partner violence and rape and women's risk factors for intimate partner violence: A multicountry cross-sectional study in Asia and the Pacific.
- Author
-
Jewkes, Rachel, Fulu, Emma, Tabassam Naved, Ruchira, Chirwa, Esnat, Dunkle, Kristin, Haardörfer, Regine, Garcia-Moreno, Claudia, null, null, and UN Multi-country Study on Men and Violence Study Team
- Subjects
INTIMATE partner violence ,RAPE ,VIOLENCE against women ,DOMESTIC violence ,WOMEN ,ABUSED women ,MEN ,RESEARCH funding ,SELF-evaluation ,DISEASE prevalence ,CROSS-sectional method - Abstract
Background: Understanding the past-year prevalence of male-perpetrated intimate partner violence (IPV) and risk factors is essential for building evidence-based prevention and monitoring progress to Sustainable Development Goal (SDG) 5.2, but so far, population-based research on this remains very limited. The objective of this study is to compare the population prevalence rates of past-year male-perpetrated IPV and nonpartner rape from women's and men's reports across 4 countries in Asia and the Pacific. A further objective is to describe the risk factors associated with women's experience of past-year physical or sexual IPV from women's reports and factors driving women's past-year experience of partner violence.Methods and Findings: This paper presents findings from the United Nations Multi-country Study on Men and Violence in Asia and the Pacific. In the course of this study, in population-based cross-sectional surveys, 5,206 men and 3,106 women aged 18-49 years were interviewed from 4 countries: Cambodia, China, Papua New Guinea (PNG), and Sri Lanka. To measure risk factors, we use logistic regression and structural equation modelling to show pathways and mediators. The analysis was not based on a written plan, and following a reviewer's comments, some material was moved to supplementary files and the regression was performed without variable elimination. Men reported more lifetime perpetration of IPV (physical or sexual IPV range 32.5%-80%) than women did experience (physical or sexual IPV range 27.5%-67.4%), but women's reports of past-year experience (physical or sexual IPV range 8.2%-32.1%) were not very clearly different from men's (physical or sexual IPV range 10.1%-34.0%). Women reported much more emotional/economic abuse (past-year ranges 1.4%-5.7% for men and 4.1%-27.7% for women). Reports of nonpartner rape were similar for men (range 0.8%-1.9% in the past year) and women (range 0.4%-2.3% in past year), except in Bougainville, where they were higher for men (11.7% versus 5.7%). The risk factor modelling shows 4 groups of variables to be important in experience of past-year sexual and/or physical IPV: (1) poverty, (2) all childhood trauma, (3) quarrelling and women's limited control in relationships, and (4) partner factors (substance abuse, unemployment, and infidelity). The population attributable fraction (PAF) was largest for quarrelling often, but the second greatest PAF was for the group related to exposure to violence in childhood. The relationship control variable group had the third highest PAF, followed by other partner factors. Currently married women were also more at risk. In the structural model, a resilience pathway showed less poverty, higher education, and more gender-equitable ideas were connected and conveyed protection from IPV. These are all amenable risk factors. This research was cross-sectional, so we cannot be sure of the temporal sequence of exposure, but the outcome being a past-year measure to some extent mitigates this problem.Conclusions: Past-year IPV indicators based on women's reported experience that were developed to track SDG 5 are probably reasonably reliable but will not always give the same prevalence as may be reported by men. Report validity requires further research. Interviews with men to track past-year nonpartner rape perpetration are feasible and important. The findings suggest a range of factors are associated with past-year physical and/or sexual IPV exposure; of particular interest is the resilience pathway suggested by the structural model, which is highly amenable to intervention and explains why combining economic empowerment of women and gender empowerment/relationship skills training has been successful. This study provides additional rationale for scaling up violence prevention interventions that combine economic and gender empowerment/relationship skills building of women, as well as the value of investing in girls' education with a view to long-term violence reduction. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
24. Monitoring and Evaluating Progress towards Universal Health Coverage in South Africa.
- Author
-
Ataguba, John E., Day, Candy, and McIntyre, Di
- Subjects
HEALTH insurance ,HEALTH equity ,HEALTH services accessibility ,HEALTH services administration ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. John E. Ataguba and colleagues illustrate progress towards UHC and its monitoring and evaluation in South Africa. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
25. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis.
- Author
-
Subbaraman, Ramnath, Nathavitharana, Ruvandhi R., Satyanarayana, Srinath, Pai, Madhukar, Thomas, Beena E., Chadha, Vineet K., Rade, Kiran, Swaminathan, Soumya, and Mayer, Kenneth H.
- Subjects
PUBLIC sector ,TUBERCULOSIS ,TUBERCULOSIS hospitals ,TUBERCULOSIS prevention ,TUBERCULOSIS treatment - Abstract
Background: India has 23% of the global burden of active tuberculosis (TB) patients and 27% of the world's "missing" patients, which includes those who may not have received effective TB care and could potentially spread TB to others. The "cascade of care" is a useful model for visualizing deficiencies in case detection and retention in care, in order to prioritize interventions.Methods and Findings: The care cascade constructed in this paper focuses on the Revised National TB Control Programme (RNTCP), which treats about half of India's TB patients. We define the TB cascade as including the following patient populations: total prevalent active TB patients in India, TB patients who reach and undergo evaluation at RNTCP diagnostic facilities, patients successfully diagnosed with TB, patients who start treatment, patients retained to treatment completion, and patients who achieve 1-y recurrence-free survival. We estimate each step of the cascade for 2013 using data from two World Health Organization (WHO) reports (2014-2015), one WHO dataset (2015), and three RNTCP reports (2014-2016). In addition, we conduct three targeted systematic reviews of the scientific literature to identify 39 unique articles published from 2000-2015 that provide additional data on five indicators that help estimate different steps of the TB cascade. We construct separate care cascades for the overall population of patients with active TB and for patients with specific forms of TB-including new smear-positive, new smear-negative, retreatment smear-positive, and multidrug-resistant (MDR) TB. The WHO estimated that there were 2,700,000 (95%CI: 1,800,000-3,800,000) prevalent TB patients in India in 2013. Of these patients, we estimate that 1,938,027 (72%) TB patients were evaluated at RNTCP facilities; 1,629,906 (60%) were successfully diagnosed; 1,417,838 (53%) got registered for treatment; 1,221,764 (45%) completed treatment; and 1,049,237 (95%CI: 1,008,775-1,083,243), or 39%, of 2,700,000 TB patients achieved the optimal outcome of 1-y recurrence-free survival. The separate cascades for different forms of TB highlight different patterns of patient attrition. Pretreatment loss to follow-up of diagnosed patients and post-treatment TB recurrence were major points of attrition in the new smear-positive TB cascade. In the new smear-negative and MDR TB cascades, a substantial proportion of patients who were evaluated at RNTCP diagnostic facilities were not successfully diagnosed. Retreatment smear-positive and MDR TB patients had poorer treatment outcomes than the general TB population. Limitations of our analysis include the lack of available data on the cascade of care in the private sector and substantial uncertainty regarding the 1-y period prevalence of TB in India.Conclusions: Increasing case detection is critical to improving outcomes in India's TB cascade of care, especially for smear-negative and MDR TB patients. For new smear-positive patients, pretreatment loss to follow-up and post-treatment TB recurrence are considerable points of attrition that may contribute to ongoing TB transmission. Future multisite studies providing more accurate information on key steps in the public sector TB cascade and extension of this analysis to private sector patients may help to better target interventions and resources for TB control in India. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
26. Early Childhood Developmental Status in Low- and Middle-Income Countries: National, Regional, and Global Prevalence Estimates Using Predictive Modeling.
- Author
-
McCoy, Dana Charles, Peet, Evan D., Ezzati, Majid, Danaei, Goodarz, Black, Maureen M., Sudfeld, Christopher R., Fawzi, Wafaie, and Fink, Günther
- Subjects
- *
CHILD development , *CHILD psychology , *COGNITIVE development , *DISEASE prevalence , *LOW-income countries , *MIDDLE-income countries , *REGRESSION analysis , *COGNITION , *ECONOMICS , *EMOTIONS , *MATHEMATICAL models , *RESEARCH funding , *SOCIAL skills , *THEORY ,DEVELOPING countries - Abstract
Background: The development of cognitive and socioemotional skills early in life influences later health and well-being. Existing estimates of unmet developmental potential in low- and middle-income countries (LMICs) are based on either measures of physical growth or proxy measures such as poverty. In this paper we aim to directly estimate the number of children in LMICs who would be reported by their caregivers to show low cognitive and/or socioemotional development.Methods and Findings: The present paper uses Early Childhood Development Index (ECDI) data collected between 2005 and 2015 from 99,222 3- and 4-y-old children living in 35 LMICs as part of the Multiple Indicator Cluster Survey (MICS) and Demographic and Health Surveys (DHS) programs. First, we estimate the prevalence of low cognitive and/or socioemotional ECDI scores within our MICS/DHS sample. Next, we test a series of ordinary least squares regression models predicting low ECDI scores across our MICS/DHS sample countries based on country-level data from the Human Development Index (HDI) and the Nutrition Impact Model Study. We use cross-validation to select the model with the best predictive validity. We then apply this model to all LMICs to generate country-level estimates of the prevalence of low ECDI scores globally, as well as confidence intervals around these estimates. In the pooled MICS and DHS sample, 14.6% of children had low ECDI scores in the cognitive domain, 26.2% had low socioemotional scores, and 36.8% performed poorly in either or both domains. Country-level prevalence of low cognitive and/or socioemotional scores on the ECDI was best represented by a model using the HDI as a predictor. Applying this model to all LMICs, we estimate that 80.8 million children ages 3 and 4 y (95% CI 48.1 million, 113.6 million) in LMICs experienced low cognitive and/or socioemotional development in 2010, with the largest number of affected children in sub-Saharan Africa (29.4.1 million; 43.8% of children ages 3 and 4 y), followed by South Asia (27.7 million; 37.7%) and the East Asia and Pacific region (15.1 million; 25.9%). Positive associations were found between low development scores and stunting, poverty, male sex, rural residence, and lack of cognitive stimulation. Additional research using more detailed developmental assessments across a larger number of LMICs is needed to address the limitations of the present study.Conclusions: The number of children globally failing to reach their developmental potential remains large. Additional research is needed to identify the specific causes of poor developmental outcomes in diverse settings, as well as potential context-specific interventions that might promote children's early cognitive and socioemotional well-being. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Smoking Behavior and Healthcare Expenditure in the United States, 1992-2009: Panel Data Estimates.
- Author
-
Lightwood, James and Glantz, Stanton A.
- Subjects
SMOKING cessation ,MEDICAL care financing ,HEALTH ,SMOKING ,REGRESSION analysis ,PUBLIC health & economics ,MEDICAL care costs ,RESEARCH funding ,DISEASE prevalence ,CROSS-sectional method ,EVALUATION of human services programs ,ECONOMICS - Abstract
Background: Reductions in smoking in Arizona and California have been shown to be associated with reduced per capita healthcare expenditures in these states compared to control populations in the rest of the US. This paper extends that analysis to all states and estimates changes in healthcare expenditure attributable to changes in aggregate measures of smoking behavior in all states.Methods and Findings: State per capita healthcare expenditure is modeled as a function of current smoking prevalence, mean cigarette consumption per smoker, other demographic and economic factors, and cross-sectional time trends using a fixed effects panel data regression on annual time series data for each the 50 states and the District of Columbia for the years 1992 through 2009. We found that 1% relative reductions in current smoking prevalence and mean packs smoked per current smoker are associated with 0.118% (standard error [SE] 0.0259%, p < 0.001) and 0.108% (SE 0.0253%, p < 0.001) reductions in per capita healthcare expenditure (elasticities). The results of this study are subject to the limitations of analysis of aggregate observational data, particularly that a study of this nature that uses aggregate data and a relatively small sample size cannot, by itself, establish a causal connection between smoking behavior and healthcare costs. Historical regional variations in smoking behavior (including those due to the effects of state tobacco control programs, smoking restrictions, and differences in taxation) are associated with substantial differences in per capita healthcare expenditures across the United States. Those regions (and the states in them) that have lower smoking have substantially lower medical costs. Likewise, those that have higher smoking have higher medical costs. Sensitivity analysis confirmed that these results are robust.Conclusions: Changes in healthcare expenditure appear quickly after changes in smoking behavior. A 10% relative drop in smoking in every state is predicted to be followed by an expected $63 billion reduction (in 2012 US dollars) in healthcare expenditure the next year. State and national policies that reduce smoking should be part of short term healthcare cost containment. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
28. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis.
- Author
-
Haacker, Markus, Fraser-Hurt, Nicole, and Gorgens, Marelize
- Subjects
CIRCUMCISION ,HIV prevention ,EPIDEMICS ,COST effectiveness ,DISEASE incidence ,PREVENTIVE health services ,HIV infections ,ECONOMICS - Abstract
Background: Empirical studies and population-level policy simulations show the importance of voluntary medical male circumcision (VMMC) in generalized epidemics. This paper complements available scenario-based studies (projecting costs and outcomes over some policy period, typically spanning decades) by adopting an incremental approach-analyzing the expected consequences of circumcising one male individual with specific characteristics in a specific year. This approach yields more precise estimates of VMMC's cost-effectiveness and identifies the outcomes of current investments in VMMC (e.g., within a fiscal budget period) rather than of investments spread over the entire policy period.Methods/findings: The model has three components. We adapted the ASSA2008 model, a demographic and epidemiological model of the HIV epidemic in South Africa, to analyze the impact of one VMMC on HIV incidence over time and across the population. A costing module tracked the costs of VMMC and the resulting financial savings owing to reduced HIV incidence over time. Then, we used several financial indicators to assess the cost-effectiveness of and financial return on investments in VMMC. One circumcision of a young man up to age 20 prevents on average over 0.2 HIV infections, but this effect declines steeply with age, e.g., to 0.08 by age 30. Net financial savings from one VMMC at age 20 are estimated at US$617 at a discount rate of 5% and are lower for circumcisions both at younger ages (because the savings occur later and are discounted more) and at older ages (because male circumcision becomes less effective). Investments in male circumcision carry a financial rate of return of up to 14.5% (for circumcisions at age 20). The cost of a male circumcision is refinanced fastest, after 13 y, for circumcisions at ages 20 to 25. Principal limitations of the analysis arise from the long time (decades) over which the effects of VMMC unfold-the results are therefore sensitive to the discount rate applied, and more generally to the future course of the epidemic and of HIV/AIDS-related policies pursued by the government.Conclusions: VMMC in South Africa is highly effective in reducing both HIV incidence and the financial costs of the HIV response. The return on investment is highest if males are circumcised between ages 20 and 25, but this return on investment declines steeply with age. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
29. Mobile Phones As Surveillance Tools: Implementing and Evaluating a Large-Scale Intersectoral Surveillance System for Rabies in Tanzania.
- Author
-
Mtema, Zacharia, Changalucha, Joel, Cleaveland, Sarah, Elias, Martin, Ferguson, Heather M., Halliday, Jo E. B., Haydon, Daniel T., Jaswant, Gurdeep, Kazwala, Rudovick, Killeen, Gerry F., Lembo, Tiziana, Lushasi, Kennedy, Malishee, Alpha D., Mancy, Rebecca, Maziku, Matthew, Mbunda, Eberhard M., Mchau, Geofrey J. M., Murray-Smith, Roderick, Rysava, Kristyna, and Said, Khadija
- Subjects
ELECTRONIC surveillance ,MEDICAL screening ,RABIES ,MEDICAL technology ,PATIENT compliance ,PATIENTS ,MANAGEMENT - Abstract
Katie Hampson and colleagues describe their experience of developing and deploying a large-scale rabies surveillance system based on mobile phones in southern Tanzania. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Financial Risk Protection and Universal Health Coverage: Evidence and Measurement Challenges.
- Author
-
Saksena, Priyanka, Hsu, Justine, and Evans, David B.
- Subjects
HEALTH insurance ,HEALTH funding ,HEALTH services administration ,HEALTH services accessibility ,PUBLIC health - Abstract
: As part of a PLOS Collection on universal health coverage, Priyanka Saksena and colleagues examine existing measures of financial risk protection and suggest future developments that could be valuable in monitoring progress towards universal health coverage. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
31. Monitoring and Evaluating Progress towards Universal Health Coverage in China.
- Author
-
Meng, Qingyue and Xu, Ling
- Subjects
HEALTH insurance ,PUBLIC health ,MEDICAL care use ,HEALTH policy ,HEALTH funding - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Qingyue Meng and colleagues illustrate progress towards UHC and its monitoring and evaluation in China. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Monitoring and Evaluating Progress towards Universal Health Coverage in Thailand.
- Author
-
Tangcharoensathien, Viroj, Limwattananon, Supon, Patcharanarumol, Walaiporn, and Thammatacharee, Jadej
- Subjects
HEALTH insurance ,MEDICAL care use ,HEALTH policy ,PERIODIC health examinations ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Walaiporn Patcharanarumol and colleagues illustrate progress towards UHC and its monitoring and evaluation in Thailand. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. Monitoring and Evaluating Progress towards Universal Health Coverage in Chile.
- Author
-
Aguilera, Ximena, Castillo-Laborde, Carla, Ferrari, Manuel Nájera-De, Delgado, Iris, and Ibañez, Ciro
- Subjects
HEALTH insurance ,HEALTH services administration ,HEALTH funding ,HEALTH equity ,PUBLIC health - Abstract
This paper by Ximena Paz Aguilera and colleagues is a country case study for the Universal Health Coverage Collection, organized by WHO. It illustrates progress towards UHC and its monitoring and evaluation in Chile. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Monitoring and Evaluating Progress towards Universal Health Coverage in Bangladesh.
- Author
-
Huda, Tanvir, Khan, Jahangir A. M., Ahsan, Karar Zunaid, Jamil, Kanta, and Arifeen, Shams El
- Subjects
HEALTH insurance ,HEALTH services accessibility ,HEALTH services administration ,HEALTH policy ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Tanvir Mahmudul Huda and colleagues illustrate progress towards UHC and its monitoring and evaluation in Bangladesh. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Monitoring and Evaluating Progress towards Universal Health Coverage in Estonia.
- Author
-
Lai, Taavi, Habicht, Triin, and Jesse, Maris
- Subjects
HEALTH insurance ,PRIMARY health care ,HEALTH policy ,HEALTH funding ,PUBLIC health - Abstract
This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Taavi Lai and colleagues illustrate progress towards UHC and its monitoring and evaluation in Estonia. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Monitoring and Evaluating Progress towards Universal Health Coverage in India.
- Author
-
Devadasan, Narayanan, Ghosh, Soumitra, Nandraj, Sunil, and Sundararaman, T.
- Subjects
HEALTH insurance ,HEALTH promotion ,PALLIATIVE treatment ,PRIMARY health care ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. N. Devadasan and colleagues illustrate progress towards UHC and its monitoring and evaluation in India. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
37. Monitoring and Evaluating Progress towards Universal Health Coverage in Brazil.
- Author
-
Barreto, Mauricio L., Rasella, Davide, Machado, Daiane B., Aquino, Rosana, Lima, Diana, Garcia, Leila P., Boing, Alexandra C., Santos, Jackson, Escalante, Juan, Aquino, Estela M. L., and Travassos, Claudia
- Subjects
HEALTH insurance ,HEALTH services accessibility ,HEALTH services administration ,PRIMARY health care ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Mauricio Barreto and colleagues illustrates progress towards UHC and its monitoring and evaluation in Brazil. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Monitoring and Evaluating Progress towards Universal Health Coverage in Singapore.
- Author
-
Tan, Kelvin Bryan, Tan, Woan Shin, Bilger, Marcel, and Ho, Calvin W. L.
- Subjects
HEALTH insurance ,HEALTH promotion ,HEALTH services accessibility ,HEALTH services administration ,NON-communicable diseases ,PUBLIC health ,PREVENTION - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Woan Shin Tan and colleagues illustrate progress towards UHC and its monitoring and evaluation in Singapore. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review.
- Author
-
Golder, Su, Loke, Yoon K., Wright, Kath, and Norman, Gill
- Subjects
ADVERSE health care events ,MEDICAL care ,META-analysis ,CLINICAL trials ,MEDICAL publishing ,DRUG side effects ,LITERATURE ,RESEARCH funding ,RISK assessment ,SYSTEMATIC reviews ,PUBLICATION bias - Abstract
Background: We performed a systematic review to assess whether we can quantify the underreporting of adverse events (AEs) in the published medical literature documenting the results of clinical trials as compared with other nonpublished sources, and whether we can measure the impact this underreporting has on systematic reviews of adverse events.Methods and Findings: Studies were identified from 15 databases (including MEDLINE and Embase) and by handsearching, reference checking, internet searches, and contacting experts. The last database searches were conducted in July 2016. There were 28 methodological evaluations that met the inclusion criteria. Of these, 9 studies compared the proportion of trials reporting adverse events by publication status. The median percentage of published documents with adverse events information was 46% compared to 95% in the corresponding unpublished documents. There was a similar pattern with unmatched studies, for which 43% of published studies contained adverse events information compared to 83% of unpublished studies. A total of 11 studies compared the numbers of adverse events in matched published and unpublished documents. The percentage of adverse events that would have been missed had each analysis relied only on the published versions varied between 43% and 100%, with a median of 64%. Within these 11 studies, 24 comparisons of named adverse events such as death, suicide, or respiratory adverse events were undertaken. In 18 of the 24 comparisons, the number of named adverse events was higher in unpublished than published documents. Additionally, 2 other studies demonstrated that there are substantially more types of adverse events reported in matched unpublished than published documents. There were 20 meta-analyses that reported the odds ratios (ORs) and/or risk ratios (RRs) for adverse events with and without unpublished data. Inclusion of unpublished data increased the precision of the pooled estimates (narrower 95% confidence intervals) in 15 of the 20 pooled analyses, but did not markedly change the direction or statistical significance of the risk in most cases. The main limitations of this review are that the included case examples represent only a small number amongst thousands of meta-analyses of harms and that the included studies may suffer from publication bias, whereby substantial differences between published and unpublished data are more likely to be published.Conclusions: There is strong evidence that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study. The inclusion of unpublished data can also reduce the imprecision of pooled effect estimates during meta-analysis of adverse events. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
40. Make Data Sharing Routine to Prepare for Public Health Emergencies.
- Author
-
Chretien, Jean-Paul, Rivers, Caitlin M., and Johansson, Michael A.
- Subjects
DATA analysis ,ZIKA Virus Epidemic, 2015-2016 ,EBOLA virus disease ,PUBLIC health ,VIRUSES ,MANAGEMENT ,COMMUNICATION ,EPIDEMICS ,MEDICAL emergencies ,ACCESS to information - Abstract
Jean-Paul Chretien and colleagues argue that recent Ebola and Zika virus outbreaks highlight the importance of data sharing in scientific research. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Why Most Clinical Research Is Not Useful.
- Author
-
Ioannidis, John P. A.
- Subjects
CLINICAL trials ,SCIENTIFIC knowledge ,PRAGMATISM ,SCIENTIFIC errors ,MEDICAL research - Abstract
John Ioannidis argues that problem base, context placement, information gain, pragmatism, patient centeredness, value for money, feasibility, and transparency define useful clinical research. He suggests most clinical research is not useful and reform is overdue. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
42. "Real-Time" Monitoring of Under-Five Mortality: Lessons for Strengthened Vital Statistics Systems.
- Author
-
Bryce, Jennifer, Amouzou, Agbessi, Victora, Cesar G., Jones, Gareth, Silva, Romesh, Hill, Kenneth, Black, Robert E., null, null, and RMM Working Group
- Subjects
VITAL statistics ,MORTALITY ,LOW-income countries ,CHILD death ,PUBLIC health ,DECISION making - Abstract
Bryce and colleagues, reflect on lessons that can be learned from the Real-Time Monitoring of Under-Five Mortality Collection. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. "Real-Time" Monitoring of Under-Five Mortality: A Vision Tempered by Reality.
- Author
-
Bryce, Jennifer, null, null, and RMM Working Group
- Subjects
VITAL statistics ,PUBLIC health research ,MORTALITY ,CHILD mortality - Abstract
Jennifer Bryce and the RMM Working Group describe the origin and rationale of the Real-Time Monitoring of Under-Five Mortality Collection. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Attacks on medical workers in Syria: Implications for conflict research.
- Author
-
Spagat, Michael
- Subjects
SYRIAN Civil War, 2011- ,HEALTH facilities ,MEDICAL personnel ,HUMANITARIAN law ,RESEARCH - Abstract
In a Perspective linked to the Research Article by Haar and colleagues, Michael Spagat discusses the challenges and importance of conducting research on mortality in regions affected by violent conflicts. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. What is the value of multidisciplinary care for chronic kidney disease?
- Author
-
Fluck, Richard J. and Taal, Maarten W.
- Subjects
CHRONIC kidney failure ,CARDIOVASCULAR diseases risk factors ,NEPHROLOGY ,CARDIOVASCULAR diseases ,MEDICAL care costs ,PROGNOSIS ,COST effectiveness - Abstract
In a Persepctive, Richard Fluck and Maarten Taal discuss the potential value of implementing multidisciplinary care programs for chronic kidney disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
46. From Joint Thinking to Joint Action: A Call to Action on Improving Water, Sanitation, and Hygiene for Maternal and Newborn Health.
- Author
-
Velleman, Yael, Mason, Elizabeth, Graham, Wendy, Benova, Lenka, Chopra, Mickey, Campbell, Oona M. R., Gordon, Bruce, Wijesekera, Sanjay, Hounton, Sennen, Esteves Mills, Joanna, Curtis, Val, Afsana, Kaosar, Boisson, Sophie, Magoma, Moke, Cairncross, Sandy, and Cumming, Oliver
- Subjects
SANITARY engineering ,NATURAL resources ,ENVIRONMENTAL health ,COMMUNICABLE diseases ,PUBLIC health - Abstract
: Yael Velleman and colleagues argue for stronger integration between the water, sanitation, and hygiene (WASH) and maternal and newborn health sectors. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Cancer Genomics: Large-Scale Projects Translate into Therapeutic Advances.
- Author
-
Mardis, Elaine R. and Ladanyi, Marc
- Subjects
GENOMICS ,TRANSLATIONAL research ,ONCOLOGY ,INDIVIDUALIZED medicine ,CANCER genetics ,TUMOR treatment ,MEDICAL research ,TUMORS - Abstract
Elaine Mardis and Marc Ladanyi discuss how large-scale genomics has driven advances in cancer translational medicine, with a focus on publications in this month's Special Issue. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
48. Monitoring Intervention Coverage in the Context of Universal Health Coverage.
- Author
-
Boerma, Ties, AbouZahr, Carla, Evans, David, and Evans, Tim
- Subjects
HEALTH insurance ,HEALTH promotion ,PALLIATIVE treatment ,MEDICAL rehabilitation ,MEDICAL informatics - Abstract
: As part of the Universal Health Coverage Collection, Ties Boerma and colleagues discuss monitoring intervention coverage related to the full spectrum of UHC, including health promotion and disease prevention, treatment, rehabilitation, and palliation. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Achieving the HIV Prevention Impact of Voluntary Medical Male Circumcision: Lessons and Challenges for Managing Programs.
- Author
-
Sgaier, Sema K., Reed, Jason B., Thomas, Anne, and Njeuhmeli, Emmanuel
- Subjects
AIDS prevention ,CIRCUMCISION ,MALE reproductive organ surgery ,HIV infection complications ,HIV prevention ,MEDICAL research - Abstract
: In this Collection Review, Sema Sgaier and colleagues highlight the key points from the PLOS Volunteer Medical Male Circumcision Collection and give some recommendations on the way forward. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. Monitoring and Evaluating Progress towards Universal Health Coverage in Ghana.
- Author
-
Nyonator, Frank, Ofosu, Anthony, Segbafah, Mabel, and d'Almeida, Selassi
- Subjects
HEALTH insurance ,HEALTH services administration ,HEALTH equity ,HEALTH funding ,PUBLIC health - Abstract
: This paper is a country case study for the Universal Health Coverage Collection, organized by WHO. Mabel Segbafah and colleagues illustrate progress towards UHC and its monitoring and evaluation in Ghana. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.